Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Welcomes UK Incentive Plan To Tackle AMR

Executive Summary

There has been an enthusiastic response from industry to the news that NICE and NHS England are to explore a new payment model that pays pharmaceutical companies based on how valuable their medicines are to the country's health service, rather than on the quantity of antibiotics sold.

You may also be interested in...



How To Pay For AMR Drugs: Pull, Not Just Push

Encouraging companies to develop new antimicrobials requires a new way of thinking about value assessment. A UK five-year AMR plan takes this into consideration.

Merck And The 'Strange Business' Of Antibiotics

Antibacterials have been part of Merck's mission for decades, despite the market challenges, and it's expecting two new approvals this year. Infectious disease VP Joan Butterton talks about tackling those challenges and incentives that may help the industry address antimicrobial resistance.

Destiny Pharma's XF-73 Being Studied For Diabetic Foot Ulcers, Burns Too

One year after its IPO, UK-based Destiny Pharma's CEO tells Scrip it's on track with US development of its lead antimicrobial asset XF-73 for prevention of post-operative infections and will also develop a new formulation to treat infections in diabetic foot ulcers and burn wounds.

Related Content

Topics

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel